The iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity represent a comprehensive, internationally developed framework aimed at addressing obesity as a chronic, relapsing, progressive disease with major cardiovascular (CV) implications. Developed by a multidisciplinary panel of 33 experts from 23 countries, including cardiologists, endocrinologists, nephrologists, nutritionists and surgeons, the guideline seeks to translate contemporary evidence into pragmatic recommendations adaptable to diverse healthcare settings, including resource-constrained environments.
Obesity is a global public health crisis, affecting over one billion people worldwide. It is strongly associated with cardiovascular disease (CVD), type 2 diabetes, chronic kidney disease, heart failure and premature mortality. Despite its prevalence and impact, obesity remains underdiagnosed and undertreated, particularly within cardiovascular care. The guideline emphasises that obesity management is central to cardiovascular prevention and should be embedded in routine CV risk assessment and care pathways.
The document was informed by a structured literature review. Evidence was graded using a modified ESC framework, with Class I–III recommendations and Levels of Evidence A–C. The guideline integrates an economic adjustment model stratifying recommendations across three resource settings: resource sufficient, somewhat limited, and severely limited. This ensures global applicability, particularly in low- and middle-income countries.
Obesity is defined as abnormal or excessive adiposity that impairs health. Body mass index (BMI) remains the principal diagnostic tool, with ethnicity-specific cut-offs recommended (e.g. lower thresholds for Asian populations). However, BMI alone is insufficient; the guideline highlights the importance of waist circumference, waist-to-height ratio, and clinical assessment of adiposity-related complications.
Obesity staging should incorporate both anthropometric measures and clinical consequences, including hypertension, dyslipidaemia, diabetes, sleep apnoea, and heart failure. Routine screening for obesity and related comorbidities is strongly recommended in cardiovascular practice.
Lifestyle intervention is the cornerstone of obesity treatment. All patients should receive structured counselling on diet, physical activity and behavioural modification.
Dietary recommendations favour calorie reduction tailored to individual preferences and cultural context, with emphasis on Mediterranean-style or plant-forward dietary patterns where feasible. Even modest weight loss (5–10%) confers clinically meaningful improvements in cardiometabolic risk.
Physical activity recommendations include at least 150–300 minutes of moderate-intensity aerobic exercise weekly, alongside resistance training to preserve muscle mass. The guideline stresses the importance of reducing sedentary time.
Behavioural interventions should incorporate goal-setting, self-monitoring, cognitive behavioural techniques, and, where available, structured multidisciplinary programmes. In severely limited settings, brief clinician-delivered counselling and community-based programmes are prioritised.
Anti-obesity medications are recommended as adjuncts to lifestyle modification in patients with BMI ≥30 kg/m², or ≥27 kg/m² with comorbidities.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual incretin therapies are central to current pharmacological management. Semaglutide 2.4 mg weekly and tirzepatide have demonstrated substantial weight reductions (often exceeding 15–20%) in large randomised trials. Beyond weight loss, semaglutide has shown cardiovascular benefit in patients with established CVD and overweight/obesity, reducing major adverse cardiovascular events.
Other pharmacotherapies discussed include orlistat, naltrexone–bupropion, and phentermine-containing regimens (where approved). These agents produce more modest weight loss and may be limited by side effects or contraindications, particularly in patients with cardiovascular disease. Drug selection should consider efficacy, safety profile, comorbidities, cost, and availability.
In resource-limited settings, access to newer incretin-based therapies may be constrained. In such cases, emphasis remains on intensive lifestyle intervention, with older pharmacotherapies considered where appropriate and available.
The guideline underscores that obesity treatment should aim not merely at weight reduction but at reducing cardiovascular risk and improving outcomes. Weight loss improves blood pressure, glycaemic control, lipid profiles and inflammatory markers. In heart failure with preserved ejection fraction (HFpEF), obesity management plays a particularly important role.
Obesity-related sarcopenia and cachexia are also addressed, with caution against excessive lean mass loss during rapid weight reduction. Resistance training and adequate protein intake are encouraged to preserve muscle mass.
Metabolic (bariatric) surgery is recommended for individuals with severe obesity (generally BMI ≥40 kg/m², or ≥35 kg/m² with significant comorbidities) when lifestyle and pharmacological therapies are insufficient. Surgery provides the most durable weight loss and can induce remission of type 2 diabetes, improve hypertension and dyslipidaemia, and reduce cardiovascular events and mortality.
Procedures such as sleeve gastrectomy and Roux-en-Y gastric bypass are highlighted. Careful patient selection, multidisciplinary assessment, and long-term follow-up are essential. In severely limited settings, surgical access may be restricted, requiring prioritisation of highest-risk patients.
The document addresses obesity management in older adults, patients with established CVD, chronic kidney disease, and those with frailty. Individualisation of therapy is emphasised, balancing benefits of weight reduction against risks such as sarcopenia or nutritional deficiencies.
A distinctive feature of the guideline is its global implementation framework. Recommendations are stratified according to resource availability, enabling adaptation across healthcare systems. Task-sharing, digital health tools, telemedicine, and community health worker engagement are proposed to expand reach.
The guideline also calls for policy-level interventions, including improved access to effective pharmacotherapies, insurance coverage, public health initiatives targeting obesogenic environments, and stigma reduction.
The iCARDIO Alliance Guidelines position obesity as a central cardiovascular disease requiring proactive, evidence-based, and globally adaptable management. By integrating lifestyle, pharmacological and surgical strategies within a resource-sensitive framework, the document provides a practical roadmap for clinicians worldwide. Its overarching message is clear: effective obesity management is fundamental to cardiovascular prevention and must become standard of care across diverse healthcare settings.
Source: Journal of Cachexia, Sarcopenia and Muscle
Image Credit: iStock
